Phase-III Studie: HECTOR Topotecan plus Carboplatin (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin) -Intergroup Study of NOGGO und Studiengruppe.
R4 簡聖軒 指導老師: 高志平大夫. Maturation of B lymphocyte DLBCL classification Double hit DLBCL MYC/BCL-2 co-expression DLBCL Conclusion and take home.
Which difference should we target? Alberto Sobrero Ospedale San Martino IRCCS Genova, Italy.
Ovarian Cancer: Standards of Care and New Opportunities Robert L. Coleman, M.D. Professor & Vice Chair, Clinical Research Department of Gynecologic Oncology.
NiCCC (G143) (ENGOT-GYN1) A Randomised Phase II study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma.
Accelerated Approval Update 2005 Ramzi Dagher, MD DDOP/OODP/CDER/FDA.
Navigating uncertainty in policy decision making about new cancer drugs: A qualitative study of Canadian policymakers Presenter: Dr. S. Michelle Driedger,
MULTIPLE MYELOMA ASH 2006 UPDATE Jeffrey Wolf, MD Director, Myeloma Program UCSF.
What’s New in HER2: Current Issues in HER2 Positive Breast Cancer Kristine Abueg, RN, MSN, OCN®, CBCN ® Oncology Clinical Trials Kaiser Permanente, Roseville.
Morton Coleman, M.D. Director, Center for Lymphoma and Myeloma Weill Cornell Medical Center New York Presbyterian Hospital New York, New York Early Stage.
High costs of new drugs Carin A. Uyl-de Groot, PhD Professor of health technology assessment iBMG/iMTA, Erasmus University Rotterdam [email protected] Thanks.
2012 ALGORITHM FOR MANAGEMENT OF ADVANCED OVARIAN CANCER Bradley J. Monk, MD, FACS, FACOG Professor and Director Division of Gynecologic Oncology Department.